Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL39P38, or ribosomal protein L39 pseudogene 38, is one of many processed pseudogenes derived from the RPL39 gene. The canonical RPL39 gene encodes a ribosomal protein of the 60S large subunit and plays a role in protein synthesis in the cytoplasm[3][5]. Pseudogenes like RPL39P38 do not code for functional proteins and are not considered therapeutic targets. They are generally transcribed fragments that have arisen through retrotransposition and are present throughout the genome without regulatory or protein-coding function[3][5]. There is no evidence for direct biological activity, interaction with drugs, or use as a biomarker. The existence of multiple pseudogenes for ribosomal proteins is a common genomic feature and does not indicate a functional or disease-related role[3][4][5]. Key points: - RPL39P38 is not a functional gene or receptor; it is a noncoding pseudogene[5]. - It cannot be considered a therapeutic target, nor is it a druggable entity[3][5]. - No biological or disease roles, pharmacological interactions, or safety concerns are known for this entity. - The entry is likely incorrect or misleading if intended as a therapeutic drug target[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ribosomal protein L39 pseudogene 38 (RPL39P38).